Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tis… (NCT05989035) | Clinical Trial Compass
CompletedNot Applicable
Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tissue in Healthy Participants
United States31 participantsStarted 2020-08-31
Plain-language summary
This study is being done to collect Adipose tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that Adipose tissue in the laboratory.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Group 1 cohort are male or female participants between 18 and 30 years old
✓. Group 2 cohort are male or female participants ≥ 65 years old
✓. Body mass index (BMI) ≤ 40 kg/m2
✓. Weight stable (±5 kg) for the last 3 months prior to the Screening visit
✓. Sedentary (\<20 min of activity, 3x/week).
✓. Able to speak and understand written and spoken English
✓. Willing and able to comply with scheduled visits, laboratory tests, and other study procedures
✓. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study
Exclusion criteria
✕. Diagnosis of type 1 diabetes mellitus
✕. Diagnosis of type 2 diabetes mellitus (HbA1C ≥ 6.5)
✕. Insulin use and use of any other medications for diabetes.
✕. Use of metformin for polycystic ovarian disease